Immunotherapy for Ph-adult acute lymphoblastic leukemia: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.01.008
- VernacularTitle:成年人Ph-急性淋巴细胞白血病的免疫治疗:第56届美国血液学会年会报道
- Author:
Qingsong YIN
;
Yongping SONG
- Publication Type:Journal Article
- Keywords:
Leukemia,lymphocytic,acute;
Philadelphia chromosome;
Immunotherapy;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(1):23-26
- CountryChina
- Language:Chinese
-
Abstract:
Outcome of patients with adult acute lymphoblastic leukemia (ALL) is poor,and even worse among patients with relapsed/refractory ALL (R/R ALL).New treatments must be taken to overcome drugresistance to conventional chemotherapy for ALL.Humanized monoclonal antibody and chimeric antigen receptor gene modified T cells have become the focus of treatment in ALL.Lots of clinical trials in multiple research centers are in progress,and the results constantly upgrade which is effectively bring better curative effect and prognosis for R/R ALL patients.This is one of the hot topics at the 56th ASH annual meeting.
